TABLE 4.
Multivariate analysis of progression‐free survival
| HR | 95% CI | p value | |
|---|---|---|---|
| Immune‐related liver injury | |||
| No (n = 233) | 1 | 0.827–2.503 | 0.198 |
| Yes (n = 30) | 1.439 | ||
| Immune‐related endocrine dysfunction | |||
| No (n = 234) | 1 | 0.335–1.157 | 0.134 |
| Yes (n = 29) | 0.623 | ||
| Proteinuria | |||
| No (n = 176) | 1 | 0.457–1.009 | 0.056 |
| Yes (n = 87) | 0.679 | ||
| Fatigue | |||
| No (n = 191) | 1 | 0.716–1.768 | 0.610 |
| Yes (n = 72) | 1.125 | ||
| Decreased appetite | |||
| No (n = 202) | 1 | 0.398–2.490 | 0.089 |
| Yes (n = 61) | 1.528 | ||
| Hypertension | |||
| No (n = 211) | 1 | 0.326–0.854 | 0.009 |
| Yes (n = 52) | 0.527 | ||
| Age (years) | |||
| <75 (n = 144) | 1 | 0.650–1.346 | 0.720 |
| ≥75 (n = 119) | 0.936 | ||
| Sex | |||
| Female (n = 55) | 1 | 0.813–1.959 | 0.299 |
| Male (n = 208) | 1.262 | ||
| ECOG‐PS | |||
| 0 (n = 216) | 1 | 0.787–2.208 | 0.294 |
| ≥1 (n = 47) | 1.318 | ||
| Etiology | |||
| Viral (n = 136) | 1 | 0.704–1.452 | 0.951 |
| Non‐viral (n = 127) | 1.011 | ||
| α‐fetoprotein (ng/ml) | |||
| <100 (n = 170) | 1 | 1.111–2.427 | 0.013 |
| ≥100 (n = 93) | 1.642 | ||
| BCLC stage | |||
| ≤B (n = 121) | 1 | 0.698–1.580 | 0.814 |
| ≥C (n = 142) | 1.050 | ||
| Child–Pugh score | |||
| ≤6 (n = 243) | 1 | 0.785–2.732 | 0.231 |
| ≥7 (n = 20) | 1.464 |
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG‐PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio.